Once-Monthly GLP-1: The Coming Shift From Weekly to Monthly Dosing

Why dosing cadence is a strategic variable

Weight-loss magnitude has been the headline number for every GLP-1 drug since semaglutide. But on the ground, in real-world use, the biggest determinant of how much weight someone actually loses is not the drug's theoretical magnitude — it is how consistently they take it. Adherence studies of the GLP-1 class show that real-world weight loss is typically 30-50% of trial weight loss, and the gap is overwhelmingly explained by missed doses, early discontinuation, and gaps in supply.

Anything that improves adherence improves real-world outcomes more than incremental gains in efficacy. Daily-to-weekly dosing (the move from liraglutide to semaglutide) is part of why semaglutide has dominated the market — not because it produces dramatically more weight loss, but because weekly is easier to keep up than daily. Weekly-to-monthly is potentially a larger jump in the same direction.

The pharmacology that allows monthly dosing

To dose a drug once monthly, its half-life has to be long enough that blood levels at the end of the month are still in the therapeutic range. For peptide drugs, this is hard. Semaglutide has been engineered with albumin-binding and DPP-4-resistant modifications to push its half-life to about a week — that is already a tour-de-force of peptide engineering. Going from a one-week to a four-week half-life with peptide chemistry is mostly not feasible.

The way to get there is to switch scaffolds. Antibodies have half-lives measured in weeks because of how they are recycled in plasma via the neonatal Fc receptor. By building a GLP-1 receptor agonist onto an antibody backbone (as MariTide does), a drug developer can inherit the antibody's long half-life while keeping the GLP-1 activity. The cost is manufacturing complexity and product cost — antibody-based drugs are more expensive than peptides — but the cadence advantage may be worth it.

Adherence — the unsung determinant of outcomes

Real-world data on weekly GLP-1 drugs paints a sobering picture. Of patients who start semaglutide for weight loss, roughly half discontinue within a year. The reasons cluster: side effects (particularly during titration), cost and insurance friction, supply gaps, and simple regimen fatigue — having to remember and execute a self-injection week after week, year after year.

Monthly dosing addresses several of these directly:

• Regimen simplicity — one event per month instead of four.
• Injection-site rotation and fatigue — fewer needles, fewer site-related issues.
• Travel and lifestyle — easier to plan around twelve monthly events than fifty-two weekly ones.
• Forgetfulness — a missed monthly dose is much more memorable than a missed weekly one.

None of these change the drug's biological efficacy. But they all push real-world outcomes closer to trial outcomes by improving how consistently the drug is actually taken.

The trade-offs of long half-lives

Long half-lives have real costs, and they are not always advertised in the headline weight-loss numbers:

Slower titration. A drug with a four-week half-life takes roughly 16-20 weeks to reach steady state at a new dose — four to five half-lives, the same pharmacokinetic rule as any other drug. That is much slower than weekly drugs, where steady state arrives in about a month.

Harder to stop. If a side effect emerges, a weekly drug clears within a few weeks of stopping. A monthly drug with a long pharmacology tail may persist for months. For predictable side effects (nausea, GI distress) this is manageable. For rare and serious events it is a real concern that the FDA will weigh in approval.

Forward exposure. A patient who discovers they are pregnant on monthly dosing has months of drug exposure ahead before clearance — the consideration that drove warnings on Saxenda and Wegovy. For monthly drugs, the warning is much more consequential.

These trade-offs are not deal-breakers; they are calibration variables. Slower titration extends time to therapeutic effect; harder-to-stop pharmacology argues for very careful Phase 3 safety data. Neither is unique to monthly dosing — they are the same considerations that apply to any long-acting drug — but they sharpen at this duration.

What comes after monthly

Once the field demonstrates that monthly dosing works (which MariTide's Phase 3 will largely settle), the engineering question becomes: how much longer can we go? Quarterly GLP-1 dosing is technically plausible with the right antibody scaffold and dosing strategy, though no candidate is yet in clinical development. Annual depot formulations — drugs released slowly from an implanted reservoir — are another conceptual route. These are speculative for the GLP-1 class but well-established in other therapeutic areas (depot contraceptives, long-acting antipsychotics).

The destination is unlikely to be much beyond a few months for biological drugs that produce sustained appetite suppression. The body adapts; very long dosing intervals risk losing the steady receptor occupancy that drives the weight-loss effect. But the trajectory clearly points toward less frequent dosing over the next decade.

The honest read

Once-monthly GLP-1 dosing is not just a marketing convenience — it is the most likely lever to close the gap between trial weight loss and real-world weight loss, by simply making it easier to keep taking the drug. If MariTide proves out in Phase 3, expect every major GLP-1 player to start working on monthly or longer-acting versions. The trade-offs around slower onset, harder discontinuation, and pregnancy considerations will need to be managed in labeling and clinical practice, but they are calibration problems, not fundamental obstacles. The drug class is moving toward less frequent dosing — slowly, but the direction is clear.